Search

Testosterone propionate

Currently, this drug has been discontinued in humans, but the vet application is still available as an OTC.[L1160] … [T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974.

Midazolam

[L45098] In late 2018, the intramuscular preparation was approved by the FDA for the treatment of status epilepticus in adults. … [L45098] In May 2019, the nasal spray of midazolam was approved for the acute treatment of distinctive intermittent, stereotypic seizure episodes in patients 12 years of age and older.

Phloxine B

Phloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing

Perampanel

The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™. … It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.

Pegunigalsidase alfa

[A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular

Bremelanotide

[A179683] Since then it was investigated for its place in treating sexual dysfunction in men and women but is now only indicated for women. … [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.

Hydroxyethyl ethylcellulose

Hydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.

Ferrous cysteine glycinate

Nirsevimab

[L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461] … [A254571,L44146] On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower respiratory tract disease in newborns and infants.

Tiratricol

[A274073] Tiratricol is currently being investigated in US clinical trials. … Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3).